Randomized Trialhigh evidence
Long-Term Impact of Vutrisiran in Patients With TTR Amyloidosis With Cardiomyopathy: 1-Year Efficacy and Safety Outcomes From the HELIOS-B Open-Label Extension.
Circulation·November 3, 2026·PMID 42974684
Why it mattersTransthyretin amyloidosis with cardiomyopathy is progressive and fatal; early treatment may alter disease trajectory. These long-term data show that initiating vutrisiran earlier provides sustained benefits in survival, cardiovascular events, and functional status, reinforcing the value of prompt diagnosis and therapy.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled